well beyond tomorrow - syndermix...well beyond tomorrow about syndermix founded in 2009, syndermix...
TRANSCRIPT
Well beyond tomorrow
About SynDermix Founded in 2009, SynDermix is a Swiss clinical-stage biotechnology company financed by private investors and with the intention to list on the SIX Swiss Exchange. We focus on developing ground-breaking treatments for disorders that affect the inner and outer skin of the human body (the mucosal barriers and skin tissues) where there is an unmet medical need.
Portfolio
Our portfolio is based on 3 proprietary technology platforms:
Plant lectins: SynDermix is the only clinical-stage company with a biopharmaceuticals pipeline dedicated to the development of therapeutic recombinant plant lectins
Nitric oxide: Our nitric oxide platform is based on a proprietary formulation with the potential to overcome the challenges of releasing and stabilising nitric oxide long enough for topical therapeutic use
Vibration therapies: Interfacing state-of-the-art MedTech with digital health, the medical devices in our vibration therapies platform provide drug-free, non-invasive treatments which relieve the disruptive symptoms of specific chronic conditions with currently no satisfactory standard of care
As a side-product pipeline, we additionally leverage our technology platforms to drive a wellcare pipeline of consumer health and beauty products of natural origin.
Business Model
Our business model is to a large extent virtual, driven by a framework of in-licensing, outsourcing and out-licensing:
� SynDermix identifies and acquires the rights to promising early-stage pipeline candidates with the potential to address unmet medical need
� We define our assets’ pipeline strategy by leveraging the complementary expertise of a seasoned executive team, a broad network of Key Opinion Leaders and contracted service providers
� We outsource the execution of our pipeline milestones to world-leading service providers, until a robust demonstration of the innovation (IP) and clinical value of our assets
� Once our pipeline candidates meet their value inflection point targets, we enter into corporate partnerships for commercialisation and market access
Management TeamDieter HemmerChief Executive OfficerCarlos Camozzi, MD, PhD, MBAClinical & RegulatoryKonstantinos Efthymiopoulos, PharmD, PhD, MBAMedical Marketing & Business DevelopmentJessica Kourniakti, DPhilStrategy & MarketingRolf Küng, MBAFinance & ControllingAnthony Lockett, MD, PhD, MBAResearch & Manufacturing
Board of DirectorsThomas Mehrling, MD, PhD ChairmanDieter HemmerDelegate of the BoardKevin P. Cox, PhDMember of the BoardHans Peter Frick, Dr. iur, LL.MMember of the BoardWolfgang Werlé, BAMember of the BoardHermann A. Wirz, BAMember of the Board
ContactSynDermix AGBuochserstrasse 26370 Stans, Switzerland
SynDermix Management AGVoltastrasse 618044 Zurich, Switzerland
Tel: +41 44 366 40 16Website: www.syndermix.chEmail: [email protected]
ISIN: CH0121242769
Member of
2018
-10
-31
UK BioIndustryAssociation
Well beyond tomorrow
Plant lectins pipeline according to indication
Vibration therapies, nitric oxide & wellcare pipelines
R&D Pre-Clinical Phase I Phase II Phase III Approval
Oral mucositis
Inflammatory bowel diseases
Pulmonary diseases (e.g. cystic fibrosis)
Skin diseases
Eye disorders
Cancer
Gastrointestinal ulceration
Wound healing (e.g. diabetic foot ulcers)
Cardiometabolic
R&D Pre-Clinical Phase I Phase II Phase III Approval
Chronic rhinosinusitis
Migraine
Wound healing
Wound healing
Other dermatological indications
Wellcare
SDX-1301
SDX-3101
SDX-13
SDX-3103
SDX-13
SDX-3104
SDX-13
SDX-2101
SDX-13
SDX-21
SDX-13/14
Énielle
SDX-13
SDX-14Accelerated reviewRegulatory strategy TBD
Our partners
Intellectual property & Regulatory
Keltie Intellectual property company, London
DanubiaPatent & law office, Budapest
Virtuoso LegalIntellectual property specialists, Leeds
Granzer Regulatory consulting & services, Munich
Manufacturing
Fujifilm Diosynth Biotechnologies Biotechnologies manu–facturer, Billingham, UK
CreaholicProfessional inventors, Biel CH
Preclinical/Clinical
BluTestMicrobiology CRO, Glasgow
Eurofins Scientific Worldwide laboratory testing services
CovanceGlobal CRO & drug development services
ISSIntegrated scientific services, Biel
Corporate & Commercial
Bihrer Attorneys at LawInternational & commercial lawyers, Zurich
BioScience Valuation Biotechnology company valuators & consultants, Grainau, DE
GfKMarket research company, London
SDX-13/14
Vision, mission and values
Our vision: To work in strategic partnerships to develop life-transforming treatments in areas of unmet medical need
Our mission: To become a global player in lasting innovation, to continually make a positive difference in the health and lives of patients worldwide
Values: We maintain a commitment to values which we believe foster successful teamwork and partnerships — to integrity, dedication and fairness — to innovation and to sustainability
Vibration therapies
Nitric oxide
Wellcare product